Genentech, a member of the Roche Group, achieved positive results from a Phase II study of RG16781, an investigational glycine reuptake inhibitor (GRI) for the treatment of schizophrenia. The data showed a clinically meaningful reduction in the negative symptoms of schizophrenia, as well as beneficial changes in personal and social functioning. The study measured improvements in patients with predominantly negative symptoms of schizophrenia who received RG1678 in combination with second-generati...